We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Energizer (ENR) Beats Earnings & Revenue Estimates in Q2
Read MoreHide Full Article
Energizer Holdings Inc. (ENR - Free Report) reported strong second-quarter fiscal 2018 results. Maintaining the earnings beat streak, Energizer’s adjusted earnings per share (EPS) of 45 cents beat the Zacks Consensus Estimate of 42 cents. However, the figure was down 10% from the year-ago quarter.
Revenues of $374.4 million topped the consensus mark of $373.18 million and increased 4.3% on a year-over-year basis. Notably, this is the third-straight quarter of a revenue beat. The year-over-year revenue growth was boosted by increased organic net sales of 1.8% and favorable currency impact of 2.5%.
Despite better-than-expected results, shares of this battery maker fell 3.6% in yesterday’s trading session. Analysts believe a contraction in gross margin and year-over-year decline in earnings per share in the reported quarter may have hurt investors’ sentiments. Shares of Energizer have lost 6.2% in the past month, underperforming the industry’s decline of 4.2%.
Energizer Holdings, Inc. Price, Consensus and EPS Surprise
Batteries revenues (88.2% of total revenues) grew 6.6% year over year to $330.3 million, while revenues from Other segment (11.8%) fell 10.2% to $44.1 million.
In Americas, the company recorded revenues of $224.1 million, up 2.6% from last-year quarter. Revenues from International were $150.3 million, up 7% from the year-ago quarter.
Margins
Gross margin contracted 180 basis points (bps) to 45% due to less favorable overhead absorption in the current quarter, unfavorable product mix driven by changes related to portfolio optimization and increased commodity costs. Selling, general and administrative expenses,excluding acquisition and integration costs, amounted to $87.7 million, reflecting a decrease of $3.5 million from the year-ago quarter.
Other Financial Details
Energizer, which carries a Zacks Rank #3 (Hold), ended the quarter with cash and cash equivalents of $490.3 million, long-term debt of $977.3 million and shareholders' equity of $44.7 million.
Year-to-date cash flow from operations in the quarter was $160.6 million. Free cash flow amounted to $149.3 million and adjusted free cash flow amounted to $152.8 million or 16.1% of net sales.
Further, on a year-to-date basis, the company repurchased shares worth $50 million.
Guidance
For fiscal 2018, Energizer continues to expect earnings per share in the band of $3.30-$3.40.
Organic revenues are expected to rise low-single digits. Moreover, favorable forex movement is likely to boost sales by 1-1.5%.
However, gross margin are now expected to be flat to up 25 bps, excluding acquisition and integration costs, from the year-ago quarter from the earlier announced increase of 50 bps. Per management, the change in the outlook reflects the impact of increased commodities costs and transportation expenses.
Capex is still expected in the range of $30-$35 million. Adjusted free cash flow is anticipated in the band of $240-$250 million.
Inter Parfums, Inc. (IPAR - Free Report) has a long-term earnings growth rate of 12.3% and a Zacks Rank #1.
Lamb Weston Holdings, Inc. (LW - Free Report) has a long-term earnings growth rate of 12% and a Zacks Rank #1.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Energizer (ENR) Beats Earnings & Revenue Estimates in Q2
Energizer Holdings Inc. (ENR - Free Report) reported strong second-quarter fiscal 2018 results. Maintaining the earnings beat streak, Energizer’s adjusted earnings per share (EPS) of 45 cents beat the Zacks Consensus Estimate of 42 cents. However, the figure was down 10% from the year-ago quarter.
Revenues of $374.4 million topped the consensus mark of $373.18 million and increased 4.3% on a year-over-year basis. Notably, this is the third-straight quarter of a revenue beat. The year-over-year revenue growth was boosted by increased organic net sales of 1.8% and favorable currency impact of 2.5%.
Despite better-than-expected results, shares of this battery maker fell 3.6% in yesterday’s trading session. Analysts believe a contraction in gross margin and year-over-year decline in earnings per share in the reported quarter may have hurt investors’ sentiments. Shares of Energizer have lost 6.2% in the past month, underperforming the industry’s decline of 4.2%.
Energizer Holdings, Inc. Price, Consensus and EPS Surprise
Energizer Holdings, Inc. Price, Consensus and EPS Surprise | Energizer Holdings, Inc. Quote
Quarterly Details
Batteries revenues (88.2% of total revenues) grew 6.6% year over year to $330.3 million, while revenues from Other segment (11.8%) fell 10.2% to $44.1 million.
In Americas, the company recorded revenues of $224.1 million, up 2.6% from last-year quarter. Revenues from International were $150.3 million, up 7% from the year-ago quarter.
Margins
Gross margin contracted 180 basis points (bps) to 45% due to less favorable overhead absorption in the current quarter, unfavorable product mix driven by changes related to portfolio optimization and increased commodity costs. Selling, general and administrative expenses,excluding acquisition and integration costs, amounted to $87.7 million, reflecting a decrease of $3.5 million from the year-ago quarter.
Other Financial Details
Energizer, which carries a Zacks Rank #3 (Hold), ended the quarter with cash and cash equivalents of $490.3 million, long-term debt of $977.3 million and shareholders' equity of $44.7 million.
Year-to-date cash flow from operations in the quarter was $160.6 million. Free cash flow amounted to $149.3 million and adjusted free cash flow amounted to $152.8 million or 16.1% of net sales.
Further, on a year-to-date basis, the company repurchased shares worth $50 million.
Guidance
For fiscal 2018, Energizer continues to expect earnings per share in the band of $3.30-$3.40.
Organic revenues are expected to rise low-single digits. Moreover, favorable forex movement is likely to boost sales by 1-1.5%.
However, gross margin are now expected to be flat to up 25 bps, excluding acquisition and integration costs, from the year-ago quarter from the earlier announced increase of 50 bps. Per management, the change in the outlook reflects the impact of increased commodities costs and transportation expenses.
Capex is still expected in the range of $30-$35 million. Adjusted free cash flow is anticipated in the band of $240-$250 million.
Stocks to Consider
WD-40 Company (WDFC - Free Report) has a long-term earnings growth rate of 10% and a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inter Parfums, Inc. (IPAR - Free Report) has a long-term earnings growth rate of 12.3% and a Zacks Rank #1.
Lamb Weston Holdings, Inc. (LW - Free Report) has a long-term earnings growth rate of 12% and a Zacks Rank #1.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>